Business ❯ Pharmaceutical Industry ❯ Market Competition ❯ Eli Lilly

Novo Nordisk

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA could issue a U.S. decision by March 28 under a faster review timeline, according to Reuters.

Lilly’s Orforglipron Pill Hits Phase 3 Goals, Clearing Path to Global Filings